Skip to main content

Table 2 Mean Resource use and cost at 14 days and 3 months

From: Controlling hypertension immediately post stroke: a cost utility analysis of a pilot randomised controlled trial

 

14 days

3 months

 

N

   

N

   
 

A

P

A

P

A-P

A

P

A

P

A-P

Mean (SE) Los (days)

112

59

11.49 (0.402)

11.36 (0.577)

0.14

105

57

43.77 (3.38)

49.47 (7.28)

-5.7

Median (IQR) LoS (days)

112

59

14 (9, 14)

14 (10,14)

0

105

57

38 (7,84)

34 (10,84)

4.0

Patients still hospitalised n (%)

112

59

76 (67.9)

38 (64.4)

3.45%

105

57

29 (27.6)

16 (28.1)

-0.45%

Study drug consumption, vials. Mean (SE)

112

59

4.7 (0.7)

5.7 (1.1)

-1.02

112

59

4.7 (0.7)

5.7 (1.1)

-1

Study drug consumption, tabs. Mean (SE)

112

59

32.53 (2.3)

45.68 (3.9)

-13.15

112

59

32.5 (2.3)

45.7 (3.9)

-13.15

Cost of hospitalisation, £, mean (SE)

112

59

2,548 (71)

2,525 (101)

23.78

105

57

8,230 (594)

9,233 (1282)

-1,003.60

Cost of study drugs, £, mean (SE)

112

59

4 (1)

0 (0)

4.14

105

59

4 (1)

0 (0)

4

Total cost, £, mean (SE)

112

59

2,553 (71)

2,525 (101)

27.93 (124)

105

57

8,234 (594)

9,233 (1282)

-999.50 (1413)

  1. SE = Standard error of the mean, IQR = Inter-quartile range, A = active (labetalol or lisinopril), P = placebo. Note figures may vary
  2. from those reported in Table 1 due to numbers of observations included (see Figure 1)